Clinical Trials Browser

NCT07252726 2026-05-27

Evaluating Dose Timing (Morning vs Evening) of Endocrine-based Therapies in Metastatic Breast and Prostate Cancers

Phase 4 Recruiting

50 enrolled

BreastGenitourinary

Breast Neoplasms, Neoplasm Metastasis, Prostatic Neoplasms

NCT07405086 2026-05-22

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

Phase 4 Recruiting

160 enrolled

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis

Clinical Trials

Evaluating Dose Timing (Morning vs Evening) of Endocrine-based Therapies in Metastatic Breast and Prostate Cancers

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

Testosterone Replacement Therapy for the Treatment of Low Testosterone in Hypogonadal Men With Localized Prostate Cancer on Active Surveillance

FC-VE

TAPBlock

SUP-R

Studying the Relationship of Patient Positioning and Intravesical Bacillus Calmette Guerin Dwell Time to Improve the Treatment of Non-muscle Invasive Bladder Cancer

NICSA

ARCH

Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer

Testosterone Replacement Therapy in Hypogonadal Patients With Prostate Cancer Under Active Surveillance

Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial

COAction

Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan

Evaluating Treatment Outcomes Using Darolutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer.

CUT-less

Transperineal, MRI-guided, Prostate Biopsy

Evaluating Fluciclovine PET in Patients With Biochemical Recurrence of Prostate Cancer and a Negative PSMA PET

PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer

Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy

Gadopiclenol in Contrast Enhanced MRI of the Prostate

CANIQOL

COBRA-NMIBC

CABOLD

Prophylactic Antibiotics for Urinary Tract Infections After Robot-Assisted Radical Cystectomy

Impact of Remimazolam on Prognosis After Bladder Cancer Surgery

GAINPCCONTROL

ITALIC-RCC

ENABLE

Preop Laxatives in Robotic Urologic Surgery

PEHAB-II

ARCO2

An Investigational Scan (18F-Fluciclovine PET-CT) for the Measurement of Therapeutic Response in Patients With Metastatic Prostate Cancer

Comparison of BCG RIVM and Russian Strains for Treating Non-Muscle-Invasive Bladder Cancer (NMIBC)

REINFORCE

Prostate MRI and Pylarify PSMA PET/CT

ADAPT-PSA

Correlation of Renal Mass Pathologic Grade and Contrast Enhanced Ultrasound (CEUS)

The Nephroprotective Effect of Metformin With Cisplatin in Bladder Cancer

TUR_BLUE

Effects of Minimal-Flow Sevoflurane and Multimodal Analgesia in Head and Neck Cancer Surgery

REDOSE

Goal-directed vs Preemptive Tranexamic Acid Administration in Non-cardiac Surgery

TASTY

Ultrasound Guided Inguinal Indocyanine Green Injection to Identify and Pre-emptively Seal Lymphatic Leaks

Self-Administered Nitrous Oxide (SANO) During Transrectal Prostate Biopsy to Reduce Patient Anxiety and Pain

TRANCE

Prothrombin Complex Concentrate vs Fresh Frozen Plasma in Goal-directed Bleeding Management in Non-cardiac Surgery

OPTI-DOSE

Effect of Perioperative Intravenous Lidocaine Infusion in Robotic-Assisted Urologic Surgery